Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Recurrence 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Leukemia 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Blast Crisis 1Appendiceal Neoplasms 1

Interventions

nilotinib 1Therapeutic Touch 1Paclitaxel 1Laparoscopy 1Fulvestrant 1Electrocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Female × nilotinib × 30 days × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡